tbuckley/cabot-search huggingface dataset:
Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis : a Preliminary Descriptive Report Of The JAK ALLO Study, a Phase II Trial Sponsored By Goelams-FIM In Collaboration With The Sfgmtc
Authors: Marie Robin, Sylvie Francois, Anne Huynh, Bruno Cassinat, Jacques-Olivier Bay, Jérôme Cornillon, Valerie Rolland, Amandine Charbonnier, Mauricette Michallet, Françoise Boyer, Stephane Vigouroux, Laure Vincent, Ibrahim Yakoub-Agha, Raphael Porcher, Gérard Socié, Brigitte Dupriez, Jean-Jacques Kiladjian
Journal: Blood (2013)
In Vitro Activity of SYK and BCR-ABL Inhibitors in Aggressive Lymphomas.
Authors: Francesco Bertoni, Andrea Rinaldi, Anna Sasso, Gianluca Gaidano, Emanuele Zucca, Silvia Uccella, Giancarlo Pruneri, Maurilio Ponzoni, Maria Grazia Tibiletti, Carlo Catapano, Franco Cavalli
Journal: Blood (2006)
Implementation of a population-based breast screening program for high-risk women in Ontario: The Ontario Breast Screening Program (OBSP) High-Risk Program.
Authors: Andrea Eisen, June Carroll, Anna M. Chiarelli, Esti Heale, Meaghan Horgan, Wendy Meschino, Linda Rabeneck, Rene Shumak, Ellen Warner
Journal: Journal of Clinical Oncology (2012)

e12034 Background: Genetic testing for mutations in BRCA1 and BRCA2 has been clinically available in Ontario since 2000. It is estimated that over 15000 individuals have been tested. Evidence from clinical trials have consistently shown that women at high risk of breast cancer such as BRCA1/2 mutation carriers benefit from breast cancer screening that includes both magnetic resonance imaging (MRI) of the breast and mammography, yet access to MRI in Ontario was variable. In 2011, Cancer Care Ontario established an expert panel to develop a protocol for expanding the Ontario Breast Screening Program, initially created for average risk women 50-74, to include MRI and mammography for eligible high risk women. Methods: The panel’s tasks included: 1. determining the criteria for high risk, 2. estimating the prevalence of high risk women, 3. selecting a model to estimate cancer risk, 4. developing a referral and assessment pathway for potentially eligible subjects to receive genetic counseling/risk assessment and screening if eligible, 5. developing educational resources, training plan and communication strategy for relevant stakeholders including primary care providers, oncologists, geneticists and genetic counselors, 6. developing indicators to permit program evaluation, 7. providing guidance for post-implementation issues such as subject eligibility and interpretation of genetic test results. Results: The program was initiated July, 2011 at 19 sites. Women aged 30-69 with and without a history of breast cancer are eligible if they 1. are BRCA1/2 mutation carriers or untested first degree relatives of carriers, 2. have a lifetime risk of breast cancer &gt;=25% based on family history, or 3. received prior radiation therapy to the chest. It is estimated that 34000 high risk women in the target age group live in Ontario. Conclusions: A population based organized screening program for high risk women that includes genetic risk assessment has been implemented in Ontario. To our knowledge, this is the first organized screening program for women at high risk of breast cancer.
Low Bone Mineral Density and High Bone Turnover In Patients with Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study
Authors: Konstantinos Anargyrou, Theodoros P. Vassilakopoulos, Konstantinos Tsionos, Panayiotis Kokkoris, Georgios Boutsikas, Maria K. Angelopoulou, Dimitrios Christoulas, Stavroula Masouridou, Maria Dimou, Athanasios Papatheodorou, Danos N. Chatzifotiadis, Panayiotis Panayiotidis, Gerasimos A. Pangalis, Photis Beris, Evangelos Terpos
Journal: Blood (2010)
Reduced Tet2 Function Contributes to Development of Peripheral T-Cell Lymphoma with Follicular Helper T-Cell-Like Features in Mice
Authors: Hideharu Muto, Mamiko Sakata-Yanagimoto, Yasuyuki Miyake, Terukazu Enami, Yuhei Kamada, Takayasu Kato, Hidekazu Nishikii, Kazumi Suzukawa, Naoya Nakamura, Seishi Ogawa, Shigeru Chiba
Journal: Blood (2012)
Knowledge gaps in the construction of rural healthy homes: A research agenda for improved low-cost housing in hot-humid Africa
Authors: Lorenz von Seidlein, Hannah Wood, Otis Sloan Brittain, Lucy Tusting, Alexa Bednarz, Salum Mshamu, Catherine Kahabuka, Jacqueline Deen, David Bell, Steve W. Lindsay, Jakob Knudsen
Journal: PLoS Medicine (2019)

points• The population of Africa is projected to increase 3-fold before 2100.Enormous resources will be required to construct houses for the predicted additional 2.5 billion new inhabitants (alongside provision of food, education, medical care, and other essentials).• This population growth presents an opportunity to incorporate housing concepts that can improve health and well-being.• Well-designed houses should provide thermal comfort and a barrier to separate diseasecarrying vectors from residents, decrease indoor pollution, and incorporate water supply, sanitation, electricity, and security.• We identified the following research priority areas: optimal building shape, roofing, vector barriers, cladding, water supply, sanitation, kitchen design, electricity supply, rural to periurban housing, and user acceptability.• Improved housing incorporating novel design elements tailored to local environments in the hot-humid regions of Africa will require investments that could come through innovative financing mechanisms for residential property.Better housing will promote well-being and health and play a critical role in achieving the Sustainable Development Goals (SDGs).
Recruitment of mSin3A and Histone Deacetylase 2 (HDAC2) by the Chromatin Remodeling Protein BRG1 Mediates Transcriptional Repression in Erythroid Progenitors.
Authors: Zhixiong Xu, Xianzhang Meng, Ying Cai, Stephen J. Brandt
Journal: Blood (2004)
SGI-110, a Novel Hypomethylating Agent, Induces the WNT Inhibitor Secreted Frizzled Related Protein-2 (SFRP2), and Down Regulates β-Catenin in Acute Myeloid Leukemia (AML) Cells
Authors: Michelle Golding, Pragya Srivastava, Golda Collamat, Smitha R James, Adam R. Karpf, Michael J. Nemeth, Elizabeth A Griffiths
Journal: Blood (2012)
Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome
Authors: Crystal Gao, Christopher McCormack, Carrie van der Weyden, Michelle S. Goh, Belinda A. Campbell, Robert Twigger, Odette Buelens, Simon J. Harrison, Christine Khoo, Stephen Lade, H. Miles Prince
Journal: Blood (2019)
Therapeutic Levels of Gene Corrected Neutrophils Following Foamy Viral Vector Mediated Gene Transfer in a Canine Model of Leukocyte Adhesion Deficiency.
Authors: Thomas R. Bauer, James M. Allen, Laura M. Tuschong, Erik M. Olson, Tanya Burkholder, Dennis D. Hickstein, David W. Russell
Journal: Blood (2005)
The Mitochondrial Carrier Homolog 2 (MTCH2) Regulates the Differentiation of AML Cells By Influencing the Localization of Pyruvate Dehydrogenase Complex and H3 and H4 Histone Acetylation
Authors: Dilshad H. Khan, Michael Mullokandov, Yan Wu, Marcela Gronda, Rose Hurren, Xiaoming Wang, Neil MacLean, Rob C. Laister, Atan Gross, Aaron D. Schimmer
Journal: Blood (2016)
Inhibiting Pathways Predicted From a Steroid Hormone Gene Signature Yields Synergistic Antitumor Effects in NSCLC
Authors: Abdulaziz A. Almotlak, Mariya Farooqui, Jill M. Siegfried
Journal: Journal of Thoracic Oncology (2019)

IntroductionMounting evidence supports a role for estrogen signaling in NSCLC progression. We previously reported a seven-gene signature that predicts prognosis in estrogen receptor β positive (ERβ+) NSCLC. The signature defines a network comprised of ER and human EGFR-2/3 (HER2/HER3) signaling.MethodsWe tested the efficacy of combining the pan-HER inhibitor, dacomitinib, with the estrogen antagonist, fulvestrant, in ERβ+ NSCLC models with differing genotypes. We assessed the potency of this combination on xenograft growth and survival of host mice, and the ability to reverse the gene signature associated with poor outcome.ResultsSynergy was observed between dacomitinib and fulvestrant in three human ERβ+ NSCLC models: 201T (wild-type EGFR), A549 (KRAS mutant), and HCC827 (EGFR 19 deletion) with combination indices of 0.1-0.6. The combination, but not single agents, completely reversed the gene signature associated with poor prognosis in a mechanism that is largely mediated by activator protein 1 downregulation. In vivo, the combination also induced tumor regression and reversed the gene signature. In HCC827 xenografts treated with the combination, survival of mice was prolonged after therapy discontinuation, tumors that recurred were less aggressive, and two mechanisms of HER inhibitor resistance involving c-Met activation and PTEN loss were blocked.ConclusionsThe combination of an ER blocker and a pan-HER inhibitor provides synergistic efficacy in different models of ERβ+ NSCLC. Our data support the use of this combination clinically, considering its ability to induce potent antitumor effects and produce a gene signature that predicts better clinical outcomes.
Human Platelets Express Functional Pannexin-1
Authors: Jaime Pereira, Kenji F Shoji, Anibal A Vargas, Juan A Orellana, Claudia G Saez, Karla Pereira, Cathy Paddock, Christopher Kuckleburg, Peter J. Newman, Diego Mezzano, Juan C Sáez
Journal: Blood (2011)
Cost‐Effectiveness of Noninvasive Screening for Alcohol‐Related Liver Fibrosis
Authors: Lars Asphaug, Maja Thiele, Aleksander Krag, Hans Olav Melberg
Journal: Hepatology (2019)

Alcohol-related liver disease is often undetected until irreversible late-stage decompensated disease manifests. Consequently, there is an unmet need for effective and economically reasonable pathways to screen for advanced alcohol-related fibrosis.We used real-world data from a large biopsy-controlled study of excessive drinkers recruited from primary and secondary care, to evaluate the cost-effectiveness of four primary care initiated strategies: (1) routine liver function tests with follow-up ultrasonography for test-positives, (2) the enhanced liver fibrosis (ELF) test with hospital liver stiffness measurement (LSM) for positives, (3) a three-tier strategy using the Forns Index to control before strategy 2, and (4) direct referral of all to LSM. We used linked decision trees and Markov models to evaluate outcomes short term (cost-per-accurate diagnosis) and long term (quality-adjusted life-years [QALYs]). For low-prevalence populations, ELF with LSM follow-up was most cost-effective, both short term (accuracy 96%, $196 per patient) and long term (incremental cost-effectiveness ratio [ICER] $5,387-$8,430/QALY), depending on whether diagnostic testing had lasting or temporary effects on abstinence rates. Adding Forns Index decreased costs to $72 per patient and accuracy to 95%. The strategy resulted in fewer QALYs due to more false negatives but an ICER of $3,012, making this strategy suited for areas with restricted access to ELF and transient elastography or lower willingness-to-pay. For high-prevalence populations, direct referral to LSM was highly cost-effective (accuracy 93%, $297 per patient), with ICERs between $490 and $1,037/QALY.Noninvasive screening for advanced alcohol-related fibrosis is a cost-effective intervention when different referral pathways are used according to the prevalence of advanced fibrosis. Patients in the primary health care sector should be tested with the ELF test followed by LSM if the test was positive, whereas direct referral to LSM is highly cost-effective in high-prevalence cohorts.
Study on the Subtypes of Dendritic Cells and the Expression of T Cell Co-Stimulating Molecules (CD80, CD86, CD40) on Dendritic Cells and B Cells in the Peripheral Blood of SAA Patients.
Authors: Zonghong Shao, Meifeng Tu, Hong Liu, Guangsheng He, Jun Shi, Jie Bai, Yanran Cao, Huaquan Wang, Limin Xin, Zhenzhu Cui, Juan Sun, Hairong Jia, Huisu Chen, Yanping Xue, Chongli Yang
Journal: Blood (2006)
Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning
Authors: Antonio Di Stasi, LM Poon, Roberto Ferro, Denai Milton, Gabriela Rondon, Sa A. Wang, Amir Hamdi, Muzaffar H. Qazilbash, Sairah Ahmed, Issa Khouri, Betul Oran, Chitra M. Hosing, Partow Kebriaei, Amin Alousi, Uday R Popat, Elizabeth J Shpall, Dean A. Lee, Katy Rezvani, Richard E Champlin, Stefan O. Ciurea
Journal: Blood (2013)
Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study
Authors: Shaji Kumar, Ravi Vij, Jonathan L. Kaufman, Joseph Mikhael, Thierry Facon, Brigitte Pegourie, Lofti Benboubker, Cristina Gasparetto, Martine Amiot, Philippe Moreau, Stefanie Alzate, Jeremy Ross, Martin Dunbar, Tu Xu, Suresh Agarwal, Joel Leverson, Paulo Maciag, Maria Verdugo, Cyrille Touzeau
Journal: Blood (2016)
A Common Signaling Node Constitute Non-Oncogene Addiction in Kinase Driven Leukemia:Mechanism of Oncogne Addiction in CML
Authors: Meenu Kesarwani, Zachary Kincaid, Ahmed Ramadan Gomma, Erika Huber, Sara Rohrabaugh, H. Leighton Grimes, Mohammad Azam
Journal: Blood (2016)
Molecular, Phenotypic and Clinical Predictors of Richter Syndrome (RS) in Chronic Lymphocytic Leukemia (CLL).
Authors: Davide Rossi, Daniela Capello, Michaela Cerri, Clara Deambrogi, Stefania Cresta, Silvia Rasi, Valeria Spina, Annarita Conconi, Francesca M. Rossi, Antonella Zucchetto, Riccardo Bomben, Valter Gattei, Gianluca Gaidano
Journal: Blood (2007)
Allogeneic Stem Cell Transplantation in Hodgkin Lymphoma: The Timing of Relapse after Autologous Transplant and Primary Refractory Disease Do Not Impact the Survival Outcomes
Authors: Francesco Spina, Serena Camilla Dalto, Simonetta Viviani, Chiara De Philippis, Anna Dodero, Lucia Farina, Vittorio Montefusco, Paolo Corradini
Journal: Blood (2015)
Therapeutic Transgene Expression From Genomic Safe Harbors In Patient-Specific Induced Pluripotent Stem Cells
Authors: Eirini P Papapetrou, Gabsang Lee, Nirav Malani, Manu Setty, Isabelle Riviere, Laxmi MS Tirunagari, Kyuichi Kadota, Shoshannah L Roth, Patricia Giardina, Agnes Viale, Christina Leslie, Frederic Bushman, Lorenz Studer, Michel Sadelain
Journal: Blood (2010)
Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC trial)
Authors: Sirpa Leppa, Judit Joergensen, Anne Tierens, Ingunn Østlie, Unn Merete Fagerli, Peter de Nully Brown, Thomas S Larsen, Susanna Mannisto, Lars Munksgaard, Martin Maisenhölder, Kaija Vasala, Peter Meyer, Mats Jerkeman, Magnus Bjorkholm, Oystein Fluge, Sirkku Jyrkkio, Elisabeth Ralfkiaer, Signe Spetalen, Marja-Liisa Karjalainen-Lindsberg, Harald Holte
Journal: Blood (2016)
Early-Life Exposure to Income Inequality and Adolescent Bullying
Authors: Olivia Jarrett, Helen Puusepp-Benazzouz, Alison Poulton
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Analysis of Dasatinib-Induced Molecular Mechanisms of Apoptosis in Hypoxia-Adopted CML Cells Utilizing Quantitative Proteomics Technology.
Authors: Yoko Tabe, Linhua Jin, Hiroko Iwanami, Saiko Kazuno, Tsutomu Fujimura, Hiromichi Matsushita, Takashi Ueno, Takashi Miida, Michael Andreeff, Marina Konopleva, Shinya Kimura
Journal: Blood (2012)
Relapsed or Refractory Multiple Myeloma: Prospective Study with Bortezomib, Non-Pegylated Liposomal Doxorubicin and Dexamethason (PAD Regimen)
Authors: Antonietta Pia Falcone, Grazia Sanpaolo, Giovanni Rossi, Carlo Bodenizza, Angelo Michele Carella, Matteo Dell' Olio, Michele Mario Greco, Antonio La Sala, Saverio Mantuano, Lorella Melillo, Emanuela Merla, Michele Nobile, Potito R Scalzulli, Silvana Capalbo, Nicola Cascavilla
Journal: Blood (2012)
Role of Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia in an HTLV-1 Non-Endemic Area of Japan.
Authors: Akio Shigematsu, Junji Tanaka, Naoki Kobayashi, Hiroshi Yasui, Motohiro Shindo, Yasutaka Kakinoki, Kakinoki Yasutaka, Satoshi Iyama, Kuroda HIroyuki, Tsutsumi Yutaka, Satoshi Hashino, Masahiro Imamura, Takanori Teshima
Journal: Blood (2012)
The Frequencies of ETV6-RUNX1 Fusion and Hyperdiploidy (&gt;50 chromosomes) in Children with Acute Lymphoblastic Leukemia Are Lower in Far East Than the West..
Authors: Der-Cherng Liang, Lee-Yung Shih, Chao-Ping Yang, Iou-Jih Hung, Hsi-Che Liu, Tang-Her Jaing, Ting-Chi Yeh, Sung-Tzu Liang, Chia-Ling Chang, En-Hui Lee, Jo-Chuan Liu, Hsien-Wen Yao, Wan-Hui Chang
Journal: Blood (2009)
A Novel PF4-Dependent P-Selectin Expression Assay (PEA) Facilitates Early Detection of Pathogenic HIT Antibodies: Implications for Diagnosis and Treatment of HIT
Authors: Anand Padmanabhan, Curtis G Jones, Shannon M Pechauer, Brian R Curtis, Daniel W. Bougie, Mia J Sullivan, Mehraboon S. Irani, Binod Dhakal, Lisa M. Baumann Kreuziger, Brenda M. Pierce, Richard H. Aster
Journal: Blood (2016)
Over-Expression of Flt3 Induces the Expression of NFkB Target Genes, cIAP-1 and IL-6.
Authors: Shinichiro Takahashi, Hideo Harigae, Mitsue Inomata, Keiko Kumura Ishii, Jonathan D. Licht, Takeshi Sasaki, Mitsuo Kaku
Journal: Blood (2004)
Early effects of surgery and radiotherapy on activity levels in patients with brain tumours: preliminary data from the BrainWear trial
Authors: Seem Dadhania, James Wei Wang, Boyu Yu, Waqar Saleem, Catherine Blake, Lillie Shahabi, Matthew Williams
Journal: Neuro-Oncology (2019)

Abstract Background BrainWear is a phase II observational clinical trial which collects data on patient activity levels, fatigue, Quality of Life (QoL) and imaging in patients with brain tumours Methods Newly diagnosed patients were offered wrist worn accelerometers (Axivity AX3) to be worn continuously throughout their treatment (surgery, chemoradiotherapy or radiotherapy) to monitor physical activity. We collected standardised measures of QoL, fatigue, MRI imaging data and disease progression. Here, we report early results on activity data 5 days before and after treatment. Results Of 23 patients recruited, we report complete pre and post treatment data in 4 patients (2 HGG, 2 metastatic) who underwent craniotomy (2), fractionated radiotherapy (1) and SRS (1). Both craniotomy patients experienced an immediate 60 – 70% reduction in activity, and were successfully discharged at day 2 post-op even though their activity was still significantly reduced. Both patients recovered another 10% in their activity levels following discharge. Radiotherapy patients experienced no early change within 5 days of starting treatment. Conclusion As expected craniotomy results in much larger changes in activity levels than SRS and radical radiotherapy. Activity levels recover post craniotomy, but this takes &gt; 5 days. Using wearable activity monitors in brain tumour patients is feasible, although there are multiple practical problems. Interpreting such data will require consideration of inpatient vs. outpatient settings.
Incidence, Clinical Characteristics and Outcome of Symptomatic Thromboembolic Events (TE) in 276 Patients with Paroxysmal Nocturnal Hemoglobinurea (PNH)
Authors: Alexander Kulagin, Olesya Klimova, Alexey Dobronravov, Elena Pavlyuchenko, Elena Babenko, Vladimir Dobronravov, Boris Afanasyev
Journal: Blood (2016)
Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402
Authors: Laura F. Newell, Todd E. DeFor, Corey S. Cutler, Michael R. Verneris, Bruce R. Blazar, Joseph H. Antin, Alan Howard, Juan Wu, Margaret L. MacMillan, Angela Panoskaltsis-Mortari, Daniel J. Weisdorf, Shernan G. Holtan
Journal: Blood (2016)
Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Authors: Catherine M. Clase, Juan-Jesus Carrero, David H. Ellison, Morgan E. Grams, Brenda R. Hemmelgarn, Meg J. Jardine, Csaba P. Kovesdy, Gregory A. Kline, Gregor Lindner, Gregorio T. Obrador, Biff F. Palmer, Michael Cheung, David C. Wheeler, Wolfgang C. Winkelmayer, Roberto Pecoits-Filho, Gloria E. Ashuntantang, Stephan J.L. Bakker, George L. Bakris, Sunil Bhandari, Emmanuel A. Burdmann, Katrina L. Campbell, David M. Charytan, Deborah J. Clegg, Lilian Cuppari, David Goldsmith, Stein I. Hallan, Jiang He, Charles A. Herzog, Melanie P. Hoenig, Ewout J. Hoorn, Jens Georg Leipziger, Amanda K. Leonberg-Yoo, Edgar V. Lerma, Jose Ernesto Lopez-Almaraz, Jolanta Małyszko, Johannes F.E. Mann, Matti Marklund, Alicia A. McDonough, Masahiko Nagahama, Sankar D. Navaneethan, Bertram Pitt, Oleh M. Pochynyuk, Thyago Proença de Moraes, Zubaid Rafique, Bruce M. Robinson, Simon D. Roger, Patrick Rossignol, Adam J. Singer, Andrew Smyth, Manish M. Sood, Michael Walsh, Matthew R. Weir, Charles S. Wingo
Journal: Kidney International (2019)

Potassium disorders are common in patients with kidney disease, particularly in patients with tubular disorders and low glomerular filtration rate. A multidisciplinary group of researchers and clinicians met in October 2018 to identify evidence and address controversies in potassium management. The issues discussed encompassed our latest understanding of the regulation of tubular potassium excretion in health and disease; the relationship of potassium intake to cardiovascular and kidney outcomes, with increasing evidence showing beneficial associations with plant-based diet and data to suggest a paradigm shift from the idea of dietary restriction toward fostering patterns of eating that are associated with better outcomes; the paucity of data on the effect of dietary modification in restoring abnormal serum potassium to the normal range; a novel diagnostic algorithm for hypokalemia that takes into account the ascendency of the clinical context in determining cause, aligning the educational strategy with a practical approach to diagnosis; and therapeutic approaches in managing hyperkalemia when chronic and in the emergency or hospital ward. In sum, we provide here our conference deliberations on potassium homeostasis in health and disease, guidance for evaluation and management of dyskalemias in the context of kidney diseases, and research priorities in each of the above areas.